Recurrent Wilms Tumor and Other Childhood Kidney Tumors Clinical Trial
Official title:
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors
NCT number | NCT01118078 |
Other study ID # | AREN10B2 |
Secondary ID | NCI-2011-02230CD |
Status | Completed |
Phase | N/A |
First received | May 5, 2010 |
Last updated | May 17, 2016 |
Start date | May 2010 |
Verified date | May 2016 |
Source | Children's Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.
Status | Completed |
Enrollment | 185 |
Est. completion date | |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 16 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of high-risk Wilms tumor meeting = 1 of the following criteria: - Relapsed disease - Anaplastic disease - Clear cell sarcomas of the kidney - Rhabdoid tumors - Registered on NWTS-4, NWTS-5 (now COG-Q9401), or participation in AREN03B2 protocols with clinical follow-up > 3 years - Banked frozen tumor samples and paired normal DNA available with clinical data points, including the following: - Age, race, and gender - Stage and reason for stage - Tumor weight - Associated precursor lesions (rests) - Histologic subtype - Site and time of recurrence - Days of follow-up - Time and reasons for death (e.g., tumor, toxicity, infection, or other) |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Children's Oncology Group | Monrovia | California |
Lead Sponsor | Collaborator |
---|---|
Children's Oncology Group | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Genomic gains and losses in high-risk Wilms tumor | After completion of biomarker analysis | No | |
Primary | Transcription patterns involved in the pathogenesis of Wilms tumor | After completion of biomarker analysis | No | |
Primary | Genetic mutations involved in the pathogenesis of Wilms tumor | After completion of biomarker analysis | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01305200 -
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT01614808 -
Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
|
N/A | |
Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00831844 -
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Completed |
NCT01586104 -
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
|
N/A | |
Completed |
NCT00897637 -
Gene Expression Profiles to Categorize Wilms Tumors
|
N/A | |
Completed |
NCT00309907 -
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00331643 -
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00012181 -
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
|
Phase 1 |